Early Transfer of Hospitalized Patients Incl. COVID-19 to a Virtual Hospital at Home Model - a Clinical Feasibility Study

Telemedicine Clinical Trial

— Influenz-er  

Official title:

Early Transfer of Hospitalized Patients Including COVID-19 Patients to a Virtual Hospital at Home(vHaH)Model -a Clinical Feasibility Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05087082
• Other study ID #: H-21014302
• Status: Completed
• Phase: N/A
• Start date: April 20, 2022
• Est. completion date: September 20, 2023

Study information

• Verified date: June 2023
• Source: Nordsjaellands Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will be part of a larger, 'virtual hospital-at-home' (vHaH) project called Influenz-er. vHaH is a care model designed to deliver medical care in the home, as a substitute for a continued inpatient hospital admission. This study will be a clinical feasibility study, which will be used to guide the framing and design of the final telemedicine supported vHaH model for hospitalized patients.

Description:

This study will be part of a larger, 'virtual hospital-at-home' (vHaH) project called Influenz-er. vHaH is a care model designed to deliver medical care in the home, as a substitute for a continued inpatient hospital admission. An underlying rationale for the development of vHaH is that, by avoiding the hospital environment, fragile and older persons may experience high-quality care that is associated with fewer complications, and higher treatment satisfaction for patients and their families. Various versions of home-hospital models have been implemented during the COVID-19 pandemic crisis, but in many situations out of need and so far, only very limited documented experience from sound research approaches is available in the medical literature. This study will be a clinical feasibility study, which will be used to guide the framing and design of the final telemedicine supported vHaH model for hospitalized patients including epidemic patients. We apply our experience from 5 months of clinical small scale testing (Sept 2021 - Jan 2022) of the light version of the final vHaH model on hospitalized patients (the technology and workflows of the vHaH model were tested by in-patients under their hospital stay) to implement this novel model in the safest possible way. The vHaH model will be offered exclusively to moderately ill (not severely ill) patients with respiratory infections including COVID-19. The overall aim of Influenz-er, is to develop and implement a novel telemedicine monitoring and communication model, that will enable safe admission of epidemic patients in their homes. We will implement this novel model in the safest possible way, and initially offer the vHaH model to patients conventionally admitted with COVID-19 illness or other lower respiratory tract infections causing pneumonia. Conversion to vHaH admission will be effectuated after an assessment by a medical infectious disease specialist if the patient is assessed to be ready to continue the hospital admission safely from home, under continued monitoring and treatment responsibility by the hospital. Based on a Cochrane review this innovative alternative to conventional hospitalization, is expected to benefit patients who will remain in the comfort of their own homes. This model could potentially increase patient and next of kin quality of life and treatment satisfaction, decrease risks of nosocomial complications and increase availability of emotional support from next of kin. A hospital based Virtual Epidemic Center (VEC) is the center of the project, from where medical staff will monitor and communicate with patients admitted at home. Vital parameters and patient reported outcomes will be collected using a smart phone/tablet-based app. All data will be collected and processed in an algorithm to predict the impact of changes on disease severity. Algorithm and direct patient data will be displayed in real-time at the hospital in the VEC, allowing medical staff to continuously monitor their patients. In addition, daily virtual ward rounds conducted by staff in the VEC and when relevant by medical doctors (MD) from specialties of relevance to the patients' illness(es) will ensure close communication and relevant clinical assessments. A mobile medical team consisting of nurses and medical doctors (MD), will perform in-person patient evaluations, administer medication and perform other required daytime routine medical tasks. The Influenz-er project governance structure consists of a Steering Committee with representation by the project partners Nordsjællands Hospital, University of Southern Denmark and Innovation Fund Denmark, an international Advisory Board and a national Consulting Group. Head of Clinical Research at Nordsjællands Hospital, Professor Thea Kølsen Fischer is principle investigator and project manager. The project team includes clinical experts with expertise within management of COVID-19 as well as health economic senior experts, PhD students, administrative research and innovation coordinators and health tech developers. The objective of this feasibility study is to investigate and analyze relevant factors for admitting adult patients with LTRI including COVID-19 in a vHaH model to ascertain the likelihood of completing the vHaH model successfully. Enrolment: Potential study patients will be identified by the general healthcare staff of the hospital COVID-19 ward, after a minimum of 24 hours of observation and conventional care, in order to ensure that the patients are in a stable phase of the disease. The healthcare staff of the hospital COVID-19 ward will be trained in, and instructed to, recognize potential eligible patients and subsequently inform the attending study personnel in the VEC. Study personnel will then assess the patients in the ward. The patients will receive oral and written information regarding the study and will be asked if they can identify a next of kin as a primary informal caregiver. Primary informal caregivers can be anyone and does not necessarily have to live with the patients or be the person who spends most time with the patients. The patients are not required to identify a primary informal caregiver in order to participate in the study. Patients with children in their household are not necessarily excluded, as the guidelines mention how to accommodate kids in the household. Current guidelines regarding self-isolation of SARS-CoV-2 positive individuals given by the Danish government will be applicable for patients admitted at home and their primary informal caregivers. If the patients do identify a primary informal caregiver this person will be contacted and the oral and written information regarding the study, will be repeated for the identified primary informal caregivers. Study consent is obtained electronically via REDCap from patients and primary informal caregivers (if any) who are still interested in participating after having received information regarding the study. This is followed by the generation of an inclusion-ID for each via REDCap. To ensure that identified primary informal caregivers are taken into consideration, it is a requirement that both patients and primary informal caregivers agree to participate in the study. The study patients must accept that primary informal caregivers have the rights to terminate the HaH-admission and demand the conversion of the HaH-admission to a conventional hospital admission at any time. If potential study patients do not accept this term it will be considered as an exclusion criterion and the patients will not be considered eligible for the study. Subsequently, the patients will be formally assessed for inclusion, in accordance with inclusion- and exclusion criteria. Included patients and primary informal caregivers (if any) will get a formal study-ID each. Study patients will receive and install the study app on a compatible device and the study personnel will ensure that study patients are educated in the basic functionality of the app. Patients who do not meet the inclusion criteria will be either permanently or temporarily excluded and will retain their inclusion-ID. Age, gender and the reason of exclusion will be noted. The first set of biometric data will be obtained within the hospital, assisted by the staff in order to secure the proper usage of the equipment. Furthermore, study patients will be equipped with a direct phone number for the VEC, which they can use to contact the personnel in the VEC independently from the app. All study patients are instructed to contact 112 in the case of a medical emergency requiring immediate medical assistance. The study patients will be instructed to measure and upload biometrical data (body temperature, blood pressure, heart rate, respiratory frequency, oxygen saturation, blood glucose) at a frequency specified by the attending Medical Doctor (MD) in accordance with medical assessment, according to standard hospital early warning score (EWS)-screening. Furthermore, patients will be instructed to complete and upload the self-assessment questionnaire along with all biometric uploads using the app. Study patients with controlled comorbidities will be monitored and treated as per usual according to local applicable guidelines, and medical specialists will be available for collegial sparring as is the case during a conventional hospitalization. The app will notify the study patients when it is time to upload a new set of biometrical and self-assessed data and notify upcoming planned virtual ward rounds. Adjustments to surveillance level will be communicated directly to study patients by attending personnel in the VEC. After all relevant information has been confidently delivered and the patient has demonstrated capability to use the app correctly the study patients will be admitted at home by the VEC MD on duty. All study patients will be offered a free transfer home. If the study patients are still dependent on supplemental oxygen this will be installed in their home prior to the home admission, and the patients and their relatives will receive thorough instructions in how to use the oxygen equipment as well as how to behave with oxygen equipment at home.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: September 20, 2023
• Est. primary completion date: September 20, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria for patients:

• Age = 18 years of age
• Signed informed written and oral consent
• Lower tract respiratory infections, including contagious infection (e.g. SARS CoV 2 and Influenza).
• Considered not ready for discharge for at least 24 hours, assessed by attending MD in the COVID-19 ward.
• Patients are self-reliant or receives sufficient formal care to be care-independent of primary informal caregiver
• - Medically eligible for vHaH, including but not solely dependent of following

conditions, assessed by the attending VEC MD:

• Actual condition assessed to be clinically stable.
• Green or yellow-tag triage based on vital parameters, including total adjusted EWS-score =6 and no adjusted single parameter score of 3 or above (See appendix 1)
• Requires less than 5L/min of oxygen supplement
• Stable or decreasing need for oxygen supplement
• Stable or decreasing paraclinical infection parameters such as C-reactive protein (CRP) etc.
• Home-based admission will be located within catchment area of the hospital (according to the official address of the individual). Exclusion criteria
• Patients who cannot participate in interaction via App
• Lack of sufficient Danish language skills to understand and interact with requirements and staff at a patient safe level
• Patient residency cannot offer isolated room (COVID-19 patients only)
• Pregnancy Inclusion criteria specific for primary informal caregivers (if any)
• Signed informed written and oral consent
• Study patient is included in the study
• Age = 18 years

Related Conditions & MeSH terms

• Epidemic Disease
• Telemedicine

Intervention

Other:
• Virtual Hospital at Home - Home admission of epidemic patients
Admitting COVID-19 patients at home

Locations

Country	Name	City	State
Denmark	Nordsjaellands Hospital	Hillerød

Sponsors (3)

Lead Sponsor	Collaborator
Nordsjaellands Hospital	Innovation Fund Denmark, University of Southern Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of all planned daily video supported ward rounds provided	successful protocol adherence is defined by 80%	through study completion, approximately 18 months
Primary	Percentage of all planned self-measurements transmitted by patient	successful protocol adherence is defined by 80%	through study completion, approximately 18 months
Primary	Percentage of all acute contact requests from patients handled within pre-defined time	successful protocol adherence is defined by 80%	through study completion, approximately 18 months
Primary	Percentage of all non-acute contact requests from patients handled within pre-defined time	successful protocol adherence is defined by 80%	through study completion, approximately 18 months
Primary	Percentage of all red alarms triggered by EWS-change handled within pre-defined time	successful protocol adherence is defined by 80%	through study completion, approximately 18 months
Primary	Percentage of all yellow alarms triggered by EWS-change handled within pre-defined time	successful protocol adherence is defined by 80%	through study completion, approximately 18 months
Primary	Number of recruited participants	recruitment success is defined as 80%	through study completion, approximately 18 months
Primary	Number of drop-out participants	success is defined by brop out less than 10%	through study completion, approximately 18 months
Primary	Number and type of outcome assessment completed by participants.		through study completion, approximately 18 months
Secondary	Patient related endpoints: Compound of clinical events	Compound of clinical events: Health care associated infections during home-based admission; Delirium during home-based admission; Thromboembolic events during home-based admission; Admittance to intensive care unit (ICU) during home-based admission; Respirator treatment following home-based admission; Intravenous antibiotic treatment during home-based admission; Intravenous antiviral treatment during home-based admission; Thirty-day readmittance rate post discharge; Mortality (associated, 7 days and 30 days)	30 days efter the discharge.
Secondary	Patient related endpoints: Loss of function	SF-36	Three months after discharge
Secondary	Patient related endpoints: Productivity losses	Number of days patient is absent from work during the period of sickness in relation to the admission, number of days patient is not able to perform daily tasks such as cooking, grocery shopping and house cleaning during the period of sickness in relation to the admission and number of days in isolation during the period of sickness in relation to the admission	Three months after discharge of patient
Secondary	Patient related endpoints: Self-perceived quality of care	Questionnaire 5	Three months after discharge of patient
Secondary	Next of kin related endpoints: Quality of Life	SF-36 (Questionnaire 3)	Three months after discharge of patient
Secondary	Next of kin related endpoints: Quality of Life	EQ-5D-5L	Three months after discharge of patient
Secondary	Next of kin related endpoints: Caregiver strain	Zarit Burden Interview (Questionnaire 6)	Two weeks after discharge of the patient
Secondary	Next of kin related endpoints: Productivity losses	Number of days next-of-kin is absent from work during the period of sickness of the patient in relation to the admission, number of days next-of-kin is not able to perform daily tasks such as cooking, grocery shopping and house cleaning during the period of sickness of the patient in relation to the admission and number of days in isolation during the period of sickness of the patient in relation to the admission	Three months after discharge of patient
Secondary	Organizational related endpoints: Costs of hospital resource use	Economic outcome	Three months after discharge of patient
Secondary	Organizational related endpoints: Number of contacts to general practitioner	Economic outcome	Three months after discharge of patient
Secondary	Organizational related endpoints: Costs of general practitioner resource use	Economic outcome	Three months after discharge of patient
Secondary	Organizational related endpoints: Total costs of health care utilization per patient	Economic outcome	Three months after discharge of patient
Secondary	Organizational related endpoints: Intervention costs	Economic outcome	Three months after discharge of patient
Secondary	Organizational related endpoints: Number of in-hospital days	Economic outcome	Three months after discharge of patient
Secondary	Organizational related endpoints: Number of outpatient visits	Economic outcome	Three months after discharge of patient
Secondary	Organizational related endpoints: Productivity losses	Economic outcome: A calculation of the costs in relation to the home admission of the patients during the feasibility study.	Three months after discharge of patient
Secondary	Health-related Quality of Life	SF36	Three months after discharge of patient
Secondary	Health-related Quality of Life	EQ-5D-5L	Three months after discharge of patient